Journal of Hepatology
Volume 48, Issue 5 , Pages 747-755 , May 2008

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

  • Stéphanie Villet

      Affiliations

    • INSERM, U871, Laboratoire des virus hépatiques et pathologies associées, Lyon F-69003, France
    • Université Lyon 1, IFR62, Lyon Est F-69008, France
    • ,
  • Christian Pichoud

      Affiliations

    • INSERM, U871, Laboratoire des virus hépatiques et pathologies associées, Lyon F-69003, France
    • Université Lyon 1, IFR62, Lyon Est F-69008, France
    • ,
  • Gaëtan Billioud

      Affiliations

    • INSERM, U871, Laboratoire des virus hépatiques et pathologies associées, Lyon F-69003, France
    • Université Lyon 1, IFR62, Lyon Est F-69008, France
    • ,
  • Luc Barraud

      Affiliations

    • Bioalliance Pharma, 49, boulevard Général Martial Valin, Paris F-75015, France
    • ,
  • Sandra Durantel

      Affiliations

    • Bioalliance Pharma, 49, boulevard Général Martial Valin, Paris F-75015, France
    • ,
  • Christian Trépo

      Affiliations

    • INSERM, U871, Laboratoire des virus hépatiques et pathologies associées, Lyon F-69003, France
    • Université Lyon 1, IFR62, Lyon Est F-69008, France
    • Hospices civils de Lyon, Hôtel Dieu, Service d’Hépatologie, Lyon F-69002, France
    • ,
  • Fabien Zoulim

      Affiliations

    • INSERM, U871, Laboratoire des virus hépatiques et pathologies associées, Lyon F-69003, France
    • Université Lyon 1, IFR62, Lyon Est F-69008, France
    • Hospices civils de Lyon, Hôtel Dieu, Service d’Hépatologie, Lyon F-69002, France
    • Corresponding Author InformationCorresponding author. Address: INSERM, U871, 151 cours Albert Thomas, 69424 Lyon cedex 03, France. Tel.: +33 472681970; fax: +33 472681971.

Received 31 October 2007 ,Revised 20 December 2007 ,Accepted 7 January 2008.

References 

  1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  2. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696
  3. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 1998;27:628–633
  4. Delaney WEt, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833–11841
  5. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatology. 1998;27:1670–1677
  6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
  7. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253–1261
  8. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085–1089
  9. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292–297
  10. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391–1398
  11. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354:1807–1812
  12. Curtis M, Zhu Y, Borroto-Esoda K. HBV rtI233V polymerase variant remains sensitive to adefovir. J Hepatol. 2007;46:S26–S27
  13. Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867–3874
  14. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31:1318–1326
  15. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385–1391
  16. Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard PM, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. Aids. 2006;20:2229–2231
  17. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488–1495
  18. Qi X, Xiong S, Yang H, Miller M, Delaney WEt. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12:355–362
  19. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–290
  20. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703–712
  21. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44:1994–1997
  22. Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, et al. In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol. 2007;45:3335–3341
  23. Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther. 2006;11:1103–1106
  24. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33:751–757
  25. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trepo C, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology. 2004;40:855–864
  26. Summers J, Smith PM, Horwich AL. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification. J Virol. 1990;64:2819–2824
  27. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with Lamivudine: a 3-year study of 145 Lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451
  28. Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat. 2006;13:278–288
  29. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902–911
  30. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531–538

☆ The authors declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript except Drs. Barraud and Durantel who are Bioalliance Pharma employees, France.

PII: S0168-8278(08)00120-7

doi: 10.1016/j.jhep.2008.01.027

Journal of Hepatology
Volume 48, Issue 5 , Pages 747-755 , May 2008

Article Tools

* Image Usage & Resolution